|Articles|June 28, 2016

Antibiotic-Resistant Bacteria Cause Multistate Outbreak

Author(s)Sarah Anwar

A multistate outbreak of Burkholderia cepacia infections might be linked to contaminated liquid docusate products in one of the states.

A multistate outbreak of Burkholderia cepacia infections might be linked to contaminated liquid docusate products in one of the states.

The Centers for Disease Control and Prevention (CDC) is conducting investigations regarding the outbreak in conjunction with the US Food and Drug Administration as well as state and local health departments and health facilities. The majority of the cases have been observed to be ventilated patients being treated in Intensive Care Units (ICU) who do not suffer from cystic fibrosis.

This is not the first outbreak caused by these bacteria. In 2004, several ICU patients in a Texas hospital were infected with B. cepacia; the infections were linked to exposure to contaminated sublingual probes. That same year a voluntary recall of over-the-counter nasal spray was issued due to contamination with the bacteria. The most recent outbreak was in 2005, when a multi-state outbreak of B. cepacia was linked to contaminated mouthwash. The patients developed several complications, including pneumonia.

According to the CDC, B. cepacia is a complex of gram-negative bacteria found in soil and water. Those at highest risk of developing severe complications from these generally antibiotic-resistant bacteria, are immunocompromised individuals, specifically those with chronic lung diseases, such as cystic fibrosis. Severity of B. cepacia infection varies among patients. While some patients are asymptomatic, others may develop serious respiratory infections.

B. cepacia can be transmitted through contact with an infected individual, contact with contaminated surfaces, through exposure to the bacteria’s natural environment, or through treatment with contaminated medicines or devices. Maintaining proper hand hygiene can reduce the risk of infection with B. cepacia.

The CDC advises against the use of liquid docusate products in patients with critical conditions, on ventilators, or who are immunosuppressed, until further information regarding the outbreak is known. Healthcare and laboratory personnel are urged to disclose all cases of B. cepacia infections in patients who do not have cystic fibrosis, to infection prevention staff, who should report the cases to state or local health authorities.


Related to this article

FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.